Skip to main content

Table 3 Antihypertensive therapy use at baseline and Week 26

From: Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials

Time point Placebo Ertugliflozin 5 mg Ertugliflozin 15 mg
Patients with one or more antihypertensive therapies
 Baselinea 337 (65.4) 353 (68.0) 336 (65.9)
 Week 26b 316 (66.8) 344 (69.5) 318 (67.5)
RAAS blockers
 Baselinea 292 (56.7) 306 (59.0) 289 (56.7)
 Week 26b 278 (58.8) 298 (60.2) 271 (57.5)
β blockers    
 Baselinea 120 (23.3) 104 (20.0) 98 (19.2)
 Week 26b 113 (23.9) 101 (20.4) 96 (20.4)
Calcium channel blockers
 Baselinea 94 (18.3) 91 (17.5) 116 (22.7)
 Week 26b 88 (18.6) 93 (18.8) 108 (22.9)
Diuretics    
 Baselinea 106 (20.6) 112 (21.6) 104 (20.4)
 Week 26b 99 (20.9) 106 (21.4) 98 (20.8)
Other antihypertensive therapy
 Baselinea 22 (4.3) 18 (3.5) 18 (3.5)
 Week 26b 22 (4.7) 18 (3.6) 18 (3.8)
  1. Every patient is counted a single time for each applicable specific medication. A patient with multiple medications within a medication category is counted a single time for that category. Data presented as number of patients (%)
  2. RAAS renin–angiotensin–aldosterone system
  3. aNumber of patients with data: 515 (placebo), 519 (ertugliflozin 5 mg), and 510 (ertugliflozin 15 mg)
  4. bNumber of patients with data: 473 (placebo), 495 (ertugliflozin 5 mg), and 471 (ertugliflozin 15 mg)